303 related articles for article (PubMed ID: 33932757)
21. The two glycolytic markers GLUT1 and MCT1 correlate with tumor grade and survival in clear-cell renal cell carcinoma.
Ambrosetti D; Dufies M; Dadone B; Durand M; Borchiellini D; Amiel J; Pouyssegur J; Rioux-Leclercq N; Pages G; Burel-Vandenbos F; Mazure NM
PLoS One; 2018; 13(2):e0193477. PubMed ID: 29481555
[TBL] [Abstract][Full Text] [Related]
22. TPX2 as a prognostic indicator and potential therapeutic target in clear cell renal cell carcinoma.
Glaser ZA; Love HD; Guo S; Gellert L; Chang SS; Herrell SD; Barocas DA; Penson DF; Cookson MS; Clark PE
Urol Oncol; 2017 May; 35(5):286-293. PubMed ID: 28108243
[TBL] [Abstract][Full Text] [Related]
23. Carbonic Anhydrase IX is not a predictor of outcomes in non-metastatic clear cell renal cell carcinoma - a digital analysis of tissue microarray.
Zerati M; Leite KR; Pontes-Junior J; Segre CC; Reis ST; Srougi M; Dall'Oglio MF
Int Braz J Urol; 2013; 39(4):484-92. PubMed ID: 24054396
[TBL] [Abstract][Full Text] [Related]
24. pT1 clear cell renal cell carcinoma: a study of the association between MIB-1 proliferative activity and pathologic features and cancer specific survival.
Cheville JC; Zincke H; Lohse CM; Sebo TJ; Riehle D; Weaver AL; Blute ML
Cancer; 2002 Apr; 94(8):2180-4. PubMed ID: 12001115
[TBL] [Abstract][Full Text] [Related]
25. Role Of Immunohistochemistry In Subtyping Renal Cell Carcinomas With Overlapping Morphological Features.
Tariq N; Mamoon N; Haroon A; Ali Z; Ahmad IN
J Ayub Med Coll Abbottabad; 2018; 30(3):325-332. PubMed ID: 30465359
[TBL] [Abstract][Full Text] [Related]
26. P53 and MDM2 Over-expression and Five-year Survival of Kidney Cancer Patients Undergoing Radical Nephrectomy--Iranian Experience.
Abolhasani M; Salarinejad S; Asgari M
Asian Pac J Cancer Prev; 2015; 16(12):5043-7. PubMed ID: 26163638
[TBL] [Abstract][Full Text] [Related]
27. Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN Project).
Brookman-May S; May M; Shariat SF; Xylinas E; Stief C; Zigeuner R; Chromecki T; Burger M; Wieland WF; Cindolo L; Schips L; De Cobelli O; Rocco B; De Nunzio C; Feciche B; Truss M; Gilfrich C; Pahernik S; Hohenfellner M; Zastrow S; Wirth MP; Novara G; Carini M; Minervini A; Simeone C; Antonelli A; Mirone V; Longo N; Simonato A; Carmignani G; Ficarra V;
Eur Urol; 2013 Sep; 64(3):472-7. PubMed ID: 22748912
[TBL] [Abstract][Full Text] [Related]
28. Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma.
Klatte T; Seligson DB; Riggs SB; Leppert JT; Berkman MK; Kleid MD; Yu H; Kabbinavar FF; Pantuck AJ; Belldegrun AS
Clin Cancer Res; 2007 Dec; 13(24):7388-93. PubMed ID: 18094421
[TBL] [Abstract][Full Text] [Related]
29. Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma.
Hakimi AA; Chen YB; Wren J; Gonen M; Abdel-Wahab O; Heguy A; Liu H; Takeda S; Tickoo SK; Reuter VE; Voss MH; Motzer RJ; Coleman JA; Cheng EH; Russo P; Hsieh JJ
Eur Urol; 2013 May; 63(5):848-54. PubMed ID: 23036577
[TBL] [Abstract][Full Text] [Related]
30. Clear cell papillary renal cell carcinoma: a clinicopathological study emphasizing ultrastructural features and cytogenetic heterogeneity.
Shi SS; Shen Q; Xia QY; Tu P; Shi QL; Zhou XJ; Rao Q
Int J Clin Exp Pathol; 2013; 6(12):2936-42. PubMed ID: 24294381
[TBL] [Abstract][Full Text] [Related]
31. Prognostic value of carbonic anhydrase IX immunohistochemical expression in renal cell carcinoma: a meta-analysis of the literature.
Zhao Z; Liao G; Li Y; Zhou S; Zou H; Fernando S
PLoS One; 2014; 9(11):e114096. PubMed ID: 25426861
[TBL] [Abstract][Full Text] [Related]
32. Clear cell renal cell carcinoma bone metastasis: What should be considered in prognostic evaluation.
Huang Z; Du Y; Zhang X; Liu H; Liu S; Xu T
Eur J Surg Oncol; 2019 Jul; 45(7):1246-1252. PubMed ID: 30760414
[TBL] [Abstract][Full Text] [Related]
33. Prognostic Significance of Membranous Carbonic Anhydrase IX Expression in Patients with Nonmetastatic Clear Cell Renal Cell Carcinoma of Different Tumor Stages.
Wang Y; Yin L; Cui Y; Wang L; Wu J; Wang J; Zhao H; Liu C; Cui Y; Zhang Y; Li X; Zhu Z; Yang L
Cancer Biother Radiopharm; 2022 Aug; 37(6):494-502. PubMed ID: 34714117
[No Abstract] [Full Text] [Related]
34. Clear cell-papillary renal cell carcinoma of the kidney not associated with end-stage renal disease: clinicopathologic correlation with expanded immunophenotypic and molecular characterization of a large cohort with emphasis on relationship with renal angiomyoadenomatous tumor.
Aron M; Chang E; Herrera L; Hes O; Hirsch MS; Comperat E; Camparo P; Rao P; Picken M; Michal M; Montironi R; Tamboli P; Monzon F; Amin MB
Am J Surg Pathol; 2015 Jul; 39(7):873-88. PubMed ID: 25970682
[TBL] [Abstract][Full Text] [Related]
35. CA9 gene: single nucleotide polymorphism predicts metastatic renal cell carcinoma prognosis.
de Martino M; Klatte T; Seligson DB; LaRochelle J; Shuch B; Caliliw R; Li Z; Kabbinavar FF; Pantuck AJ; Belldegrun AS
J Urol; 2009 Aug; 182(2):728-34. PubMed ID: 19539328
[TBL] [Abstract][Full Text] [Related]
36. Distinct immunophenotypes and prognostic factors in renal cell carcinoma with sarcomatoid differentiation: a systematic study of 19 immunohistochemical markers in 42 cases.
Yu W; Wang Y; Jiang Y; Zhang W; Li Y
BMC Cancer; 2017 Apr; 17(1):293. PubMed ID: 28449664
[TBL] [Abstract][Full Text] [Related]
37. Tumor VEGF expression correlates with tumor stage and identifies prognostically different groups in patients with clear cell renal cell carcinoma.
Minardi D; Santoni M; Lucarini G; Mazzucchelli R; Burattini L; Conti A; Bianconi M; Scartozzi M; Milanese G; Primio RD; Montironi R; Cascinu S; Muzzonigro G
Urol Oncol; 2015 Mar; 33(3):113.e1-7. PubMed ID: 25069421
[TBL] [Abstract][Full Text] [Related]
38. High mucin-7 expression is an independent predictor of adverse clinical outcomes in patients with clear-cell renal cell carcinoma.
NguyenHoang S; Liu Y; Xu L; Chang Y; Zhou L; Liu Z; Lin Z; Xu J
Tumour Biol; 2016 Nov; 37(11):15193-15201. PubMed ID: 27683054
[TBL] [Abstract][Full Text] [Related]
39. VHL and HIF-1α: gene variations and prognosis in early-stage clear cell renal cell carcinoma.
Lessi F; Mazzanti CM; Tomei S; Di Cristofano C; Minervini A; Menicagli M; Apollo A; Masieri L; Collecchi P; Minervini R; Carini M; Bevilacqua G
Med Oncol; 2014 Mar; 31(3):840. PubMed ID: 24446253
[TBL] [Abstract][Full Text] [Related]
40. Low level of Cyclin-D1 correlates with worse prognosis of clear cell renal cell carcinoma patients.
Wang QS; Li F; Liao ZQ; Li K; Yang XL; Lin YY; Zhao YL; Weng SY; Xia Y; Ye Y; Li SH; Wang CY; Lin Y
Cancer Med; 2019 Aug; 8(9):4100-4109. PubMed ID: 31183974
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]